ArticleCureus2025
Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nummular eczema (NE) is a distinctive eczematous dermatitis characterized by an eruption of coin-shaped erythematous, edematous, vesicular, and crusted patches that tend to expand as papulovesicular satellite lesions appear at the periphery and fuse with the main plaque. This pruritic disorder classically affects the extensor aspect of the extremities, trunk, and buttocks. Patients generally report poor quality of life, demanding early and effective treatment. Although topical therapy is the mainstay of management, treatment escalation may be required in severe cases. Dupilumab, a human monoclonal antibody that targets both IL-4 and IL-13, has shown efficacy for moderate to severe atopic dermatitis and other immune-mediated disorders. Here, we report a six-year-old boy with severe and extremely pruritic NE unresponsive to topical and classic systemic treatments, showing complete and maintained remission of all skin signs and symptoms under dupilumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.